- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01938820
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
July 26, 2018 updated by: Hong You, Beijing Friendship Hospital
Patients with chronic hepatitis B histologically confirmed of early cirrhosis S4 (similar to metavir F4, Ishak 5/6) are randomly assigned in a 1:1 ratio.
One arm is entecavir alone for 2 years; the other is entecavir for the first 0.5 year, entecavir plus thymosin for 1 year, entecavir for another additional 0.5 year.
Patients will be assessed at baseline, at every six months for blood count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan.
The second liver biopsy will be performed to evaluate regression rate of liver fibrosis 1.5 years after initial therapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
82
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Peking University First Hospital
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital
-
Beijing, Beijing, China, 100050
- Beijing Friendship Hospital, Capital Medical University
-
Beijing, Beijing, China, 100015
- Beijing Ditan Hospital, Capital Medical University
-
Beijing, Beijing, China, 100039
- 302 Military Hospital of China
-
Beijing, Beijing, China, 100050
- Beijing Tiantan Hospital, Capital Medical University
-
Beijing, Beijing, China, 100069
- Beijing Youan Hospital, Capital Medical University
-
Beijing, Beijing, China, 100871
- Peking University
-
Beijing, Beijing, China, 100034
- Peking University People's Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital, Southern Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050021
- Shijiazhuang Fifth Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 300030
- Tongji Hospital, Tongji Medical College, Huazhong University of Science &Technology
-
-
Jilin
-
Yanji, Jilin, China, 133000
- The Affiliated Hospital of Yanbian University
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Huashan Hospital, Fudan University
-
Shanghai, Shanghai, China, 201508
- Shanghai Public Health Clinical Center
-
Shanghai, Shanghai, China, 200080
- Shanghai First People's Hospital
-
Shanghai, Shanghai, China, 200040
- Zhongshan Hospital Fudan University
-
Shanghai, Shanghai, China, 200032
- Renji Hospital, Shanghai Jiao Tong University, School of Medicine
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030001
- The First Hospital of Shanxi Medical University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300162
- The Hospital Affiliated to Logistics University of Chinese People's Armed Police Force
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients from age 18 to 65 years old;
- Male or female;
- Treatment-naive patients with chronic hepatitis B histologically confirmed of early cirrhosis S4 (similar to metavir F4, Ishak 5/6) who consent to undergo liver biopsy before and after treatment;
- Patients with HBeAg-positive, HBVDNA>2×10<3>IU/ml or patients with HBeAg-negative, HBVDNA>2×10<2> IU/ml;
- Agree to be followed up regularly;
- Signature of written informed consent.
Exclusion Criteria:
- Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or hepatocelluar carcinoma;
- Patients who are allergic to entecavir, thymosin or their components, and those considered not suitable for drugs used in this study;
- Patients with HCV or HIV infection, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver disease or other chronic liver diseases;
- Patients with baseline AFP level higher than 100 ng/ml and possible malignant lesion on image, or AFP level higher than 100 ng/ml for more than three months;
- Creatinine >1.5×ULN;
- Patients with other uncured malignant tumors;
- Patients with severe diseases of heart, lung, kidney, brain, blood or other organs;
- Patients with any other reasons not suitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Entecavir Therapy
Entecavir monotherapy: entecavir, 0.5mg, qd, oral, for 2 years. |
anti-viral therapy
Other Names:
|
Experimental: Entecavir plus Thymosin-α
entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.
|
anti-viral therapy
Other Names:
antiviral and antifibrosis therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regression of HBV-induced liver cirrhosis
Time Frame: 1.5 to 2 years
|
Liver cirrhosis regression of 1 point by Ishak scoring system
|
1.5 to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Child-Pugh score
Time Frame: 1 year and 2 years
|
Child-Pugh score change after 1 and 2-year treatment
|
1 year and 2 years
|
HBVDNA undetectable rate
Time Frame: 1 year and 2 years
|
The HBVDNA undetectable rate after 1 and 2-year treatment.
|
1 year and 2 years
|
Fibroscan value
Time Frame: 1 year and 2 years
|
Fibroscan value change after 1 and 2-year treatment
|
1 year and 2 years
|
Life Quality
Time Frame: 1 year and 2 years
|
Life quality change after 1 and 2-year treatment by SF-36 and EQ-5D questionaire
|
1 year and 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
September 5, 2013
First Submitted That Met QC Criteria
September 5, 2013
First Posted (Estimate)
September 10, 2013
Study Record Updates
Last Update Posted (Actual)
July 27, 2018
Last Update Submitted That Met QC Criteria
July 26, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013ZX10002004-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
Clinical Trials on entecavir
-
Sunshine Lake Pharma Co., Ltd.Suspended
-
ShuGuang HospitalBeijing YouAn Hospital; Beijing Ditan Hospital; Shanghai Zhongshan Hospital; Tongji... and other collaboratorsUnknownLiver Cirrhosis Due to Hepatitis B VirusChina
-
Beijing Friendship HospitalPeking University; Peking University First Hospital; Peking University People... and other collaboratorsCompleted
-
Taipei Veterans General Hospital, TaiwanBristol-Myers SquibbCompletedProphylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B (HBVNHL)Hepatitis B | Non Hodgkin's LymphomaTaiwan
-
ShuGuang HospitalShanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Public Health Clinical... and other collaboratorsUnknown
-
Peking UniversityUnknown
-
National Taiwan University HospitalUnknownHBV/HCV Co-infectionTaiwan
-
Beijing Continent Pharmaceutical Co, Ltd.Completed
-
Taipei Veterans General Hospital, TaiwanChina Medical University Hospital; Chang Gung Memorial Hospital; Changhua Christian...UnknownChronic Hepatitis B
-
Guangxi Medical UniversityCompleted